Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-121 combination therapy in cystic fibrosis
NCT03912233Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of vanzacaftor in cystic fibrosis (CF) (6 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) and Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second. Started Apr 2019; status: completed.
02
Drugs
vanzacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03912233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912233.